145 related articles for article (PubMed ID: 26200267)
1. Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
Behera M; Pillai RN; Owonikoko TK; Kim S; Steuer C; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
J Thorac Oncol; 2015 Aug; 10(8):1142-7. PubMed ID: 26200267
[TBL] [Abstract][Full Text] [Related]
2. Favorable treatment response of bevacizumab-combined chemotherapy for advanced or recurrent invasive mucinous adenocarcinoma of the lung: A retrospective observational study.
Fujimoto K; Sekine A; Hagiwara E; Asaoka M; Ikeda S; Baba T; Komatsu S; Ogura T
Respir Investig; 2024 May; 62(3):360-364. PubMed ID: 38428089
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer: A Systematic Review of Trials Published Between 2010 and 2020.
García-Fumero R; Fernández-López C; Calleja-Hernández MÁ; Expósito-Ruiz M; Espín J; Expósito-Hernández J
Am J Clin Oncol; 2023 Oct; 46(10):433-438. PubMed ID: 37522643
[TBL] [Abstract][Full Text] [Related]
4. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma.
Dansby J; More A; Zeineddine M; Yousef A; Bent A; Dayyani F; Wolff R; Overman M; Shen JP
Oncologist; 2023 Dec; 28(12):e1303-e1305. PubMed ID: 37738316
[TBL] [Abstract][Full Text] [Related]
5. Taxane-based Chemotherapy is Effective in Metastatic Appendiceal Adenocarcinoma.
Dansby J; More A; Zeineddine M; Yousef A; Bent A; Dayyani F; Wolff R; Overman M; Shen JP
medRxiv; 2023 Jul; ():. PubMed ID: 37502847
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non-Small-Cell Lung Cancer with Brain Metastases.
Kim YH; Mishima M
J Thorac Oncol; 2015 Aug; 10(8):e76. PubMed ID: 26200284
[No Abstract] [Full Text] [Related]
7. Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non-Small-Cell Lung Cancer.
Ichihara E; Hotta K; Kiura K
J Thorac Oncol; 2015 Aug; 10(8):e79. PubMed ID: 26200288
[No Abstract] [Full Text] [Related]
8. Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non-Small-Cell Lung Cancer.
Zhang X
J Thorac Oncol; 2015 Aug; 10(8):e78-9. PubMed ID: 26200287
[No Abstract] [Full Text] [Related]
9. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study.
Yoshida K; Yamada Y
Transl Lung Cancer Res; 2015 Jun; 4(3):217-9. PubMed ID: 26207207
[No Abstract] [Full Text] [Related]
10. Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor.
Hermanson TT; Hrushesky WJ; Knopf KB; Bennett CL
J Oncol Pract; 2015 Sep; 11(5):363-4. PubMed ID: 26243648
[No Abstract] [Full Text] [Related]
11. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
Chen J; Lu Y; Zheng Y
Drug Des Devel Ther; 2015; 9():4751-60. PubMed ID: 26316712
[TBL] [Abstract][Full Text] [Related]
13. New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Curr Pharm Des; 2015; 21(32):4763-72. PubMed ID: 26219615
[TBL] [Abstract][Full Text] [Related]
14. Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
Cascone T; Heymach JV
Clin Cancer Res; 2015 Dec; 21(23):5188-90. PubMed ID: 26232370
[TBL] [Abstract][Full Text] [Related]
15. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
Aghajanian C; Goff B; Nycum LR; Wang YV; Husain A; Blank SV
Gynecol Oncol; 2015 Oct; 139(1):10-6. PubMed ID: 26271155
[TBL] [Abstract][Full Text] [Related]
16. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Modest DP; Stintzing S; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Möhler M; Jung A; Kirchner T; Heinemann V
J Clin Oncol; 2015 Nov; 33(32):3718-26. PubMed ID: 26261259
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
Syrios J; Nintos G; Georgoulias V
Expert Rev Anticancer Ther; 2015; 15(8):875-84. PubMed ID: 26204906
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Bronte G; Passiglia F; Galvano A; Russo A
Expert Opin Biol Ther; 2016; 16(1):1-5. PubMed ID: 26235195
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of rapid infusion of the initial dose of bevacizumab in patients with cancer.
Makris G; Kantzioura A; Beredima M; Karampola M; Emmanouilides C
J BUON; 2015; 20(3):923-7. PubMed ID: 26214648
[TBL] [Abstract][Full Text] [Related]
20. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
Evans TL; Cho BC; Udud K; Fischer JR; Shepherd FA; Martinez P; Ramlau R; Syrigos KN; Shen L; Chadjaa M; Wolf M
J Thorac Oncol; 2015 Aug; 10(8):1221-8. PubMed ID: 26200278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
